What are the efficacy and common side effects of avatrombopag/sucoxin?

Avatrombopag is an oral thrombopoietin receptor agonist that stimulates bone marrow megakaryocyte differentiation and proliferation by simulating the effects of endogenous thrombopoietin (TPO), thereby increasing platelet production. This mechanism makes it uniquely useful in patients with chronic liver disease-associated thrombocytopenia and primary immune thrombocytopenia (ITP). Compared with traditional glucocorticoids or intravenous immune globulin, avatrombopag has a more precise target and can target the pathological mechanism of insufficient platelet production to quickly increase platelet counts and reduce the risk of bleeding.

In chronic liver disease-associated thrombocytopenia, avatropopag is used primarily in patients requiring elective surgery or diagnostic procedures to reduce the risk of surgical bleeding. It should be noted that the drug is not used to completely restore the platelet count to the normal range, but to maintain the platelet count within the safe range of surgery to reduce the probability of bleeding during surgery or procedures. This is significantly different from traditional platelet-raising treatment methods, and also reflects the accuracy of targeted therapy.

In adult patients with chronic primary immune thrombocytopenia (ITP), avatrombopag is suitable for patients who have had poor response to previous treatments such as glucocorticoids and immunoglobulins. By promoting platelet production, the drug can increase platelet counts and reduce or prevent the risk of bleeding caused by thrombocytopenia, providing an oral, sustained-acting treatment for long-term management of platelet counts.

Although avatrombopag is generally well tolerated, there is still a risk of side effects. Common adverse reactions include headache, fatigue, diarrhea, nausea, and excessive platelet elevation. Some patients may experience mild abnormalities in liver function indicators or fluctuations in hematological parameters. Therefore, platelet count and liver function need to be monitored regularly during medication so that the dose can be adjusted in a timely manner or supportive treatment measures can be taken. For patients with a higher risk of blood clots, they should be used with caution and under the guidance of a doctor, and the risks and benefits should be evaluated.

Reference materials:https://go.drugbank.com/drugs/DB11995